Roivant Sciences (ROIV) Accumulated Expenses (2021 - 2026)

Roivant Sciences' Accumulated Expenses history runs 6 years deep, the most recent figure standing at $205.8 million for Q1 2026.

• Quarterly Accumulated Expenses rose 80.08% year-over-year to $205.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $205.8 million (up 80.08% YoY) and the FY2026 annual result came in at $205.8 million, up 80.08% from the prior year.
• Accumulated Expenses was $205.8 million for Q1 2026 at Roivant Sciences, up from $118.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $205.8 million in Q1 2026 and bottomed at $26.5 million in Q2 2025.
• A 5-year average of $93.1 million and a median of $108.3 million in 2025 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 262.82% — and 2025, when it sank 80.81%.
• Roivant Sciences' Accumulated Expenses stood at $41.9 million in 2022, then soared by 83.46% to $76.9 million in 2023, then jumped by 35.66% to $104.3 million in 2024, then gained by 13.1% to $118.0 million in 2025, then soared by 74.44% to $205.8 million in 2026.
• Business Quant data shows ROIV's Accumulated Expenses at $205.8 million in Q1 2026, $118.0 million in Q4 2025, and $108.3 million in Q3 2025.